Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.66 USD | +3.54% | -4.73% | -31.92% |
14/05 | Guggenheim Upgrades Amicus Therapeutics to Buy From Neutral With $13 Price Target | MT |
10/05 | UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.92% | 276.35Cr | |
+29.77% | 4.92TCr | |
+1.00% | 4.21TCr | |
+50.47% | 4.04TCr | |
-5.26% | 2.89TCr | |
+13.68% | 2.61TCr | |
-22.99% | 1.87TCr | |
+8.22% | 1.33TCr | |
+32.41% | 1.23TCr | |
-1.62% | 1.2TCr |
- Stock Market
- Equities
- FOLD Stock
- News Amicus Therapeutics, Inc.
- Amicus Therapeutics' Q3 Net Loss Narrows, Revenue Rises